{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:16:01Z","timestamp":1773213361512,"version":"3.50.1"},"reference-count":41,"publisher":"Zhejiang University Press","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372777"],"award-info":[{"award-number":["81372777"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1631\/jzus.b1900445","type":"journal-article","created":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T02:53:26Z","timestamp":1587869606000},"page":"315-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition","\u73af\u6c27\u5408\u9176-2 (COX-2) \u901a\u8fc7\u8c03\u63a7\u7ec6\u80de\u4e0a\u76ae\u95f4\u8d28\u8f6c\u5316 (EMT) \u4fc3\u8fdb\u5375\u5de2\u764c\u7ec6\u80de\u8fc1\u79fb\u53ca\u5176\u8010\u836f\u6027"],"prefix":"10.1631","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-8066","authenticated-orcid":false,"given":"Lin","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding-qing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"17","key":"429_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/jnci\/djr342","volume":"103","author":"JNCI Journal of the National Cancer Institute","year":"2011","unstructured":"JNCI (Journal of the National Cancer Institute), 2011. Ovarian cancer, five-year stage-specific relative survival rates (2004\u20132008). J Natl Cancer Inst, 103(17):1287. https:\/\/doi.org\/10.1093\/jnci\/djr342","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"429_CR2","doi-asserted-by":"publisher","first-page":"e43376","DOI":"10.1371\/journal.pone.0043376","volume":"7","author":"HAN al-Wadei","year":"2012","unstructured":"al-Wadei HAN, al-Wadei MH, Ullah MF, et al., 2012. Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice. PLoS ONE, 7(8):e43376. https:\/\/doi.org\/10.1371\/journal.pone.0043376","journal-title":"PLoS ONE"},{"issue":"2","key":"429_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ygyno.2006.08.008","volume":"104","author":"AP Barnes","year":"2007","unstructured":"Barnes AP, Miller BE, Kucera GL, 2007. Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. Gynecol Oncol, 104(2):443\u2013450. https:\/\/doi.org\/10.1016\/j.ygyno.2006.08.008","journal-title":"Gynecol Oncol"},{"issue":"4","key":"429_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1940-6207.CAPR-08-0206","volume":"2","author":"MM Bertagnolli","year":"2009","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, et al., 2009. Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res, 2(4):310\u2013321. https:\/\/doi.org\/10.1158\/1940-6207.Capr-08-0206","journal-title":"Cancer Prev Res"},{"issue":"22","key":"429_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A, et al., 2011. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA, 305(22):2295\u20132303. https:\/\/doi.org\/10.1001\/jama.2011.766","journal-title":"JAMA"},{"issue":"6","key":"429_CR6","doi-asserted-by":"publisher","first-page":"e65569","DOI":"10.1371\/journal.pone.0065569","volume":"8","author":"M Cervello","year":"2013","unstructured":"Cervello M, Bachvarov D, Lampiasi N, et al., 2013. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. PLoS ONE, 8(6):e65569. https:\/\/doi.org\/10.1371\/journal.pone.0065569","journal-title":"PLoS ONE"},{"key":"429_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2018.10.026","volume":"1","author":"FL Chen","year":"2019","unstructured":"Chen FL, Wen X, Lin PF, et al., 2019. HERP depletion inhibits zearalenone-induced apoptosis through autophagy activation in mouse ovarian granulosa cells. Toxicol Lett, 1: 1\u201310. https:\/\/doi.org\/10.1016\/j.toxlet.2018.10.026","journal-title":"Toxicol Lett"},{"issue":"10","key":"429_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/modpathol.2008.90","volume":"21","author":"MHS Chen","year":"2008","unstructured":"Chen MHS, Yip GWC, Tse GMK, et al., 2008. Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters. Mod Pathol, 21(10):1183\u20131191. https:\/\/doi.org\/10.1038\/modpathol.2008.90","journal-title":"Mod Pathol"},{"issue":"4","key":"429_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jhep.2010.12.043","volume":"55","author":"XL Chen","year":"2011","unstructured":"Chen XL, Lingala S, Khoobyari S, et al., 2011. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol, 55(4):838\u2013845. https:\/\/doi.org\/10.1016\/j.jhep.2010.12.043","journal-title":"J Hepatol"},{"issue":"2","key":"429_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1440-1827.2006.01925.x","volume":"56","author":"EY Cho","year":"2006","unstructured":"Cho EY, Choi Y, Chae SW, et al., 2006. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int, 56(2):62\u201370. https:\/\/doi.org\/10.1111\/j.1440-1827.2006.01925.x","journal-title":"Pathol Int"},{"issue":"15","key":"429_CR11","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1158\/1078-0432.CCR-11-3348","volume":"18","author":"LY Chung","year":"2012","unstructured":"Chung LY, Tang SJ, Sun GH, et al., 2012. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res, 18(15):4037\u20134047. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-3348","journal-title":"Clin Cancer Res"},{"issue":"54","key":"429_CR12","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1038\/sj.onc.1206920","volume":"22","author":"C Denkert","year":"2003","unstructured":"Denkert C, F\u00fcrstenberg A, Daniel PT, et al., 2003. Induction of G0\/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene, 22(54):8653\u20138661. https:\/\/doi.org\/10.1038\/sj.onc.1206920","journal-title":"Oncogene"},{"issue":"1","key":"429_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/0008-5472.CAN-03-1987","volume":"64","author":"C Denkert","year":"2004","unstructured":"Denkert C, Weichert W, Pest S, et al., 2004. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res, 64(1):189\u2013195. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-1987","journal-title":"Cancer Res"},{"issue":"4","key":"429_CR14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1200\/JCO.2002.20.4.973","volume":"20","author":"G Ferrandina","year":"2002","unstructured":"Ferrandina G, Lauriola L, Distefano MG, et al., 2002. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol, 20(4):973\u2013981. https:\/\/doi.org\/10.1200\/jco.2002.20.4.973","journal-title":"J Clin Oncol"},{"issue":"1","key":"429_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2004.07.005","volume":"95","author":"G Ferrandina","year":"2004","unstructured":"Ferrandina G, Zannoni GF, Ranelletti FO, et al., 2004. Cyclooxygenase-2 expression in borderline ovarian tumors. Gynecol Oncol, 95(1):46\u201351. https:\/\/doi.org\/10.1016\/j.ygyno.2004.07.005","journal-title":"Gynecol Oncol"},{"issue":"5","key":"429_CR16","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1073\/pnas.1803999116","volume":"116","author":"A Gartung","year":"2019","unstructured":"Gartung A, Yang J, Sukhatme VP, et al., 2019. Suppression of chemotherapy-induced cytokine\/lipid mediator surge and ovarian cancer by a dual COX-2\/sEH inhibitor. Proc Natl Acad Sci USA, 116(5):1698\u20131703. https:\/\/doi.org\/10.1073\/pnas.1803999116","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"429_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13277-014-2637-y","volume":"36","author":"C Giaginis","year":"2015","unstructured":"Giaginis C, Alexandrou P, Tsoukalas N, et al., 2015. Huantigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients\u2019 survival. Tumour Biol, 36(1):315\u2013327. https:\/\/doi.org\/10.1007\/s13277-014-2637-y","journal-title":"Tumour Biol"},{"issue":"4","key":"429_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.5306\/wjco.v5.i4.677","volume":"5","author":"RE Harris","year":"2014","unstructured":"Harris RE, Casto BC, Harris ZM, 2014. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol, 5(4):677\u2013692. https:\/\/doi.org\/10.5306\/wjco.v5.i4.677","journal-title":"World J Clin Oncol"},{"issue":"3","key":"429_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3892\/or.2012.2200","volume":"29","author":"Z Hu","year":"2013","unstructured":"Hu Z, Liu XJ, Tang ZF, et al., 2013. Possible regulatory role of Snail in NF-\u03baB-mediated changes in E-cadherin in gastric cancer. Oncol Rep, 29(3):993\u20131000. https:\/\/doi.org\/10.3892\/or.2012.2200","journal-title":"Oncol Rep"},{"issue":"5","key":"429_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu JQ, et al., 2010. Cancer statistics, 2010. CA Cancer J Clin, 60(5):277\u2013300. https:\/\/doi.org\/10.3322\/caac.20073","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"429_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4143\/crt.2014.46.1.81","volume":"46","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Yim GW, Nam EJ, et al., 2014. Synergistic effect of COX-2 inhibitor on paclitaxel-induced apoptosis in the human ovarian cancer cell line OVCAR-3. Cancer Res Treat, 46(1):81\u201392. https:\/\/doi.org\/10.4143\/crt.2014.46.L81","journal-title":"Cancer Res Treat"},{"issue":"2","key":"429_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cdp.2003.12.005","volume":"28","author":"K Kismet","year":"2004","unstructured":"Kismet K, Akay MT, Abbasoglu O, et al., 2004. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev, 28(2):127\u2013142. https:\/\/doi.org\/10.1016\/j.cdp.2003.12.005","journal-title":"Cancer Detect Prev"},{"issue":"13","key":"429_CR23","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJM199503303321303","volume":"332","author":"MW Konstan","year":"1995","unstructured":"Konstan MW, Byard PJ, Hoppel CL, et al., 1995. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med, 332(13):848\u2013854. https:\/\/doi.org\/10.1056\/nejm199503303321303","journal-title":"N Engl J Med"},{"issue":"7","key":"429_CR24","doi-asserted-by":"publisher","first-page":"1215\u00e91222","DOI":"10.1038\/bjc.2015.81","volume":"112","author":"M Koti","year":"2015","unstructured":"Koti M, Siu A, Cl\u00e9ment I, et al., 2015. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer, 112(7):1215\u00e91222. https:\/\/doi.org\/10.1038\/bjc.2015.81","journal-title":"Br J Cancer"},{"issue":"5","key":"429_CR25","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1067\/mob.2003.284","volume":"188","author":"CN Landen Jr.","year":"2003","unstructured":"Landen CN Jr., Mathur SP, Richardson MS, et al., 2003. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol, 188(5): 1174\u20131176. https:\/\/doi.org\/10.1067\/mob.2003.284","journal-title":"Am J Obstet Gynecol"},{"key":"429_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1471-2407-11-214","volume":"11","author":"F Legge","year":"2011","unstructured":"Legge F, Paglia A, D\u2019Asta M, et al., 2011. Phase II study of the combination carboplatin plus celecoxib in heavily pretreated recurrent ovarian cancer patients. BMC Cancer, 11:214. https:\/\/doi.org\/10.1186\/1471-2407-11-214","journal-title":"BMC Cancer"},{"issue":"2","key":"429_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ygyno.2003.10.053","volume":"92","author":"SF Li","year":"2004","unstructured":"Li SF, Miner K, Fannin R, et al., 2004. Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol, 92(2):622\u2013627. https:\/\/doi.org\/10.1016\/j.ygyno.2003.10.053","journal-title":"Gynecol Oncol"},{"issue":"2","key":"429_CR28","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3802\/jgo.2018.29.e32","volume":"29","author":"SS Li","year":"2018","unstructured":"Li SS, Ma J, Wong AST, 2018. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism. J Gynecol Oncol, 29(2):e32. https:\/\/doi.org\/10.3802\/jgo.2018.29.e32","journal-title":"J Gynecol Oncol"},{"issue":"10","key":"429_CR29","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1517\/14656566.8.10.1425","volume":"8","author":"RA Madan","year":"2007","unstructured":"Madan RA, Xia Q, Chang VT, et al., 2007. A retrospective analysis of cardiovascular morbidity in metastatic hormonerefractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. Expert Opin Pharmacother, 8(10):1425\u20131431. https:\/\/doi.org\/10.1517\/14656566.8.10.1425","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"429_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/cmdc.201402353","volume":"10","author":"W Neumann","year":"2015","unstructured":"Neumann W, Crews BC, S\u00e1rosi MB, et al., 2015. Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. ChemMedChem, 10(1):183\u2013192. https:\/\/doi.org\/10.1002\/cmdc.201402353","journal-title":"ChemMedChem"},{"issue":"2","key":"429_CR31","first-page":"537","volume":"33","author":"H Okamura","year":"2013","unstructured":"Okamura H, Fujiwara H, Umehara S, et al., 2013. COX-2 overexpression induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin. Anticancer Res, 33(2):537\u2013542.","journal-title":"Anticancer Res"},{"issue":"2","key":"429_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/ijgc-00009577-200503000-00011","volume":"15","author":"MR Raspollini","year":"2005","unstructured":"Raspollini MR, Amunni G, Villanucci A, et al., 2005. Increased cyclooxygenase-2 (COX-2) and p-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer, 15(2):255\u2013260. https:\/\/doi.org\/10.1136\/ijgc-00009577-200503000-00011","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"429_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/PAS.0b013e31814fa9b0","volume":"32","author":"AR Sangoi","year":"2008","unstructured":"Sangoi AR, Soslow RA, Teng NN, et al., 2008. Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential. Am J Surg Pathol, 32(2):269\u2013274. https:\/\/doi.org\/10.1097\/PAS.0b013e31814fa9b0","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"429_CR34","first-page":"99","volume":"22","author":"K Shigemasa","year":"2003","unstructured":"Shigemasa K, Tian X, Gu L, et al., 2003. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol, 22(1):99\u2013105.","journal-title":"Int J Oncol"},{"issue":"12","key":"429_CR35","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B","volume":"89","author":"RA Soslow","year":"2000","unstructured":"Soslow RA, Dannenberg AJ, Rush D, et al., 2000. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 89(12):2637\u20132645. https:\/\/doi.org\/10.1002\/1097-0142(20001215)89:12<2637::aid-cncr17>3.0.co;2-b","journal-title":"Cancer"},{"issue":"20","key":"429_CR36","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.275.20.14838","volume":"275","author":"K Subbaramaiah","year":"2000","unstructured":"Subbaramaiah K, Hart JC, Norton L, et al., 2000. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1\/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem, 275(20):14838\u201314845. https:\/\/doi.org\/10.1074\/jbc.275.20.14838","journal-title":"J Biol Chem"},{"issue":"1A","key":"429_CR37","first-page":"327","volume":"28","author":"J Wei","year":"2008","unstructured":"Wei J, Xu G, Wu M, et al., 2008. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via SRC regulation. Anticancer Res, 28(1A):327\u2013334.","journal-title":"Anticancer Res"},{"issue":"3","key":"429_CR38","doi-asserted-by":"publisher","first-page":"656","DOI":"10.4143\/crt.2016.263","volume":"49","author":"GW Yim","year":"2017","unstructured":"Yim GW, Kim HJ, Kim LK, et al., 2017. Long non-coding RNA HOXA11 antisense promotes cell proliferation and invasion and predicts patient prognosis in serous ovarian cancer. Cancer Res Treat, 49(3):656\u2013668. https:\/\/doi.org\/10.4143\/crt.2016.263","journal-title":"Cancer Res Treat"},{"issue":"6","key":"429_CR39","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s12032-014-0970-z","volume":"31","author":"XL Zhai","year":"2014","unstructured":"Zhai XL, Zhu HJ, Wang W, et al., 2014. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol, 31(6):970. https:\/\/doi.org\/10.1007\/s12032-014-0970-z","journal-title":"Med Oncol"},{"issue":"1","key":"429_CR40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13287-015-0249-0","volume":"6","author":"RR Zhang","year":"2015","unstructured":"Zhang RR, Zhang P, Wang H, et al., 2015. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44+CD117+ ovarian cancer stem cells. Stem Cell Res Ther, 6(1):262. https:\/\/doi.org\/10.1186\/s13287-015-0249-0","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"429_CR41","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/cbf.1478","volume":"26","author":"Y Zhao","year":"2008","unstructured":"Zhao Y, Yan QM, Long X, et al., 2008. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct, 26(5):571\u2013577. https:\/\/doi.org\/10.1002\/cbf.1478","journal-title":"Cell Biochem Funct"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1900445.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B1900445\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1900445.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T23:40:17Z","timestamp":1620776417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B1900445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b1900445","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"20 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lin DENG, Ding-qing FENG, and Bin LING declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}